The World Health Organization's executive board has dropped an attempt to introduce a new definition of counterfeit medicines, following concerted pressure from a coalition of India-based generic drugmakers and the governments of Brazil and India. The proposals of the International Medical Products Anti-Counterfeiting Taskforce (IMPACT) had already been amended late last year at a meeting in Bonn, Germany, to overcome concerns about legitimate generic drugs being accidentally classified as "fake" (Marketletter December 15, 2008).
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
| Headless Content Management with Blaze